

1 **Research paper**

2

3 **Gender differences in the determinants of willingness to get the**  
4 **COVID-19 vaccine among the working-age population in Japan**

5 Tomohiro Ishimaru<sup>a\*</sup>, Makoto Okawara<sup>a</sup>, Hajime Ando<sup>b</sup>, Ayako Hino<sup>c</sup>,  
6 Tomohisa Nagata<sup>d</sup>, Seiichiro Tateishi<sup>e</sup>, Mayumi Tsuji<sup>f</sup>, Shinya Matsuda<sup>g</sup>,  
7 and Yoshihisa Fujino<sup>a</sup> for the CORoNaWork Project

8 *<sup>a</sup>Department of Environmental Epidemiology, Institute of Industrial Ecological*  
9 *Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu,*  
10 *Japan; <sup>b</sup>Department of Work Systems and Health, Institute of Industrial Ecological*  
11 *Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu,*  
12 *Japan; <sup>c</sup>Department of Mental Health, Institute of Industrial Ecological Sciences,*  
13 *University of Occupational and Environmental Health, Japan, Kitakyushu, Japan;*  
14 *<sup>d</sup>Department of Occupational Health Practice and Management, Institute of Industrial*  
15 *Ecological Sciences, University of Occupational and Environmental Health, Japan,*  
16 *Kitakyushu, Japan; <sup>e</sup>Department of Occupational Medicine, School of Medicine,*  
17 *University of Occupational and Environmental Health, Japan, Kitakyushu, Japan;*  
18 *<sup>f</sup>Department of Environmental Health, School of Medicine, University of Occupational*  
19 *and Environmental Health, Japan, Kitakyushu, Japan; <sup>g</sup>Department of Preventive*  
20 *Medicine and Community Health, School of Medicine, University of Occupational and*  
21 *Environmental Health, Japan, Kitakyushu, Japan*

22

23 \*Corresponding author: Tomohiro Ishimaru, MD, MPH, PhD  
24 Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences,  
25 University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi-ku,  
26 Kitakyushu, Fukuoka 807-8555, Japan

27 Tel: +81-93-603-1611, Fax: +81-93-601-7324, email: [ishimaru@med.uoeh-u.ac.jp](mailto:ishimaru@med.uoeh-u.ac.jp)

28

29

30 **Gender differences in the determinants of willingness to get the**  
31 **COVID-19 vaccine among the working-age population in Japan**

32 Many factors are related to vaccination intentions. However, gender  
33 differences in the determinants of intention to get the coronavirus disease  
34 2019 (COVID-19) vaccine have not been fully investigated. This study  
35 examined gender differences in the determinants of willingness to get the  
36 COVID-19 vaccine among the working-age population in Japan. We  
37 conducted a cross-sectional study of Japanese citizens aged 20–65 years  
38 using an online self-administered questionnaire in December 2020.  
39 Logistic regression analysis was performed. Among 27,036 participants  
40 (13,814 men and 13,222 women), the percentage who were willing to get  
41 the COVID-19 vaccine was lower among women than among men (33.0%  
42 vs. 41.8%). Age and education level showed a gender gap regarding the  
43 association with willingness to get the COVID-19 vaccine: men who were  
44 older or had a higher level of education were more willing to get the  
45 vaccine, whereas women aged 30–49 years and those with a higher level  
46 of education showed a relatively low willingness to get the vaccine. For  
47 both men and women, marriage, higher annual household income,  
48 underlying disease, current smoking, vaccination for influenza during the  
49 current season, and fear of COVID-19 transmission were linked to a  
50 higher likelihood of being willing to get the COVID-19 vaccine. These  
51 findings give important insight into identifying target groups in need of  
52 intervention regarding COVID-19 vaccination, especially among women.  
53 Providing education about COVID-19 and influenza vaccination in the  
54 workplace may be an effective strategy to increase COVID-19 vaccine  
55 uptake.

56 **Keywords:** COVID-19; employees; infection; occupational health; SARS-CoV-2;  
57 vaccine; working age

58

## 59 **Introduction**

60 Vaccines are expected to be a key measure against the coronavirus disease 2019  
61 (COVID-19) pandemic.<sup>1</sup> Vaccine development usually takes decades, and, although a  
62 variety of COVID-19 vaccines are currently being developed at an unprecedented rate,  
63 evidence has not yet established their long-term safety.<sup>2</sup> In Japan, the COVID-19  
64 vaccination program has been administered since February 2021, with eligibility  
65 proceeding in the following order: healthcare workers, older adults (aged 65 years or  
66 older), and people with underlying diseases and caregivers working at care facilities for  
67 older adults.<sup>3</sup> Other people will become eligible for vaccination at a later date, following  
68 the populations listed above, which are the main sources of infection.<sup>4</sup> To reach herd  
69 immunity, most citizens need to be vaccinated.<sup>5</sup>

70

71 Vaccination intentions are recognized as the most important issue in the rollout of  
72 vaccination programs.<sup>6</sup> However, Japan is known for its lack of public trust in vaccines<sup>7</sup>  
73 because negative campaigns against the vaccination—highlighting scandals and severe  
74 adverse effects, for instance—have increased hesitation concerning some vaccinations  
75 over the past several decades.<sup>8-11</sup> For example, a national human papillomavirus  
76 vaccination program for girls was launched in 2013 but was discontinued after 3 months  
77 because of sensational case reports of adverse effects.<sup>12</sup> This event had a negative  
78 impact on vaccination intentions, especially among women.<sup>13</sup>

79

80 Various factors are related to COVID-19 vaccination intentions. Previous studies have  
81 reported that age, gender, race, education level, influenza vaccination status, and fear of  
82 COVID-19 transmission are associated with the willingness to get the COVID-19  
83 vaccine.<sup>14-18</sup> In Japan, willingness to get the COVID-19 vaccine was previously

84 examined in a single study of 1,100 adults, with results showing that vaccine hesitancy  
85 was higher in Japan than in other countries, particularly among women.<sup>19</sup> However,  
86 gender differences in the determinants of willingness to get the COVID-19 vaccine,  
87 such as demographic and health characteristics, influenza vaccination status, and fear of  
88 COVID-19 transmission, have not been fully investigated. Furthermore, more studies  
89 involving larger samples of the working-age population are needed. Therefore, the  
90 current study examined gender differences in the determinants of willingness to get the  
91 COVID-19 vaccine among the working-age population in Japan. This study will give  
92 important insight into identifying target groups in need of intervention regarding  
93 COVID-19 vaccination.

94

## 95 **Materials and methods**

### 96 *Study design*

97 We conducted a cross-sectional study about COVID-19 among the working-age  
98 population in Japan on December 22–26, 2020. The present article is part of a series of  
99 studies conducted under the CORoNaWork (Collaborative Online Research on the  
100 Novel-coronavirus and Work) Project.<sup>20</sup> This study was conducted during the third  
101 wave of the COVID-19 pandemic in Japan, when the number of infected people and  
102 deaths peaked.<sup>21</sup> Although COVID-19 vaccination began in December 2020 in the  
103 United Kingdom (UK) and the United States (US), Japan had not yet begun to  
104 administer COVID-19 vaccines during the survey period.<sup>22</sup> Pfizer requested a fast-track  
105 approval of its COVID-19 vaccine from the government of Japan on December 18,  
106 2020 and became the first company to receive this approval on February 14, 2021.<sup>3</sup>

107

108 Criteria for eligibility for the present study were being aged 20–65 years and currently  
109 working. Healthcare workers and caregivers were not invited to participate. We  
110 recruited study participants from the panelists of Cross Marketing Inc. (Tokyo, Japan),  
111 an Internet research company. These panelists regularly respond to self-administered  
112 Internet surveys distributed by the company, receiving tokens that can be redeemed for  
113 products and services as compensation.

114

115 For this survey, we used quota sampling by gender, residence (five districts), and  
116 occupation (office worker or other). Information on these characteristics was retrieved  
117 from the panelists' Cross Marketing Inc. registration information. Cross Marketing Inc.  
118 sent an invitation email to panelists who met the eligibility criteria, and those who were  
119 interested in the study proceeded to the survey via a hyperlink. The participants  
120 provided informed consent prior to beginning the online questionnaire. We set a quota  
121 of 1,650 participants for each of the 20 strata and ceased recruitment when the target  
122 number was reached. In total, 33,087 participants from all over Japan completed the  
123 questionnaire. After excluding invalid responses, a total of 27,036 participants  
124 remained. All participants received standard incentives through Cross Marketing Inc.  
125 (i.e., a few dollars' worth of tokens). The study was conducted according to the  
126 guidelines of the Declaration of Helsinki, and it was approved by the Ethics Committee  
127 of the University of Occupational and Environmental Health, Japan (Approval number:  
128 R2-079).

129

### 130 *Measures*

131 The survey questions included items on demographic and health characteristics,  
132 influenza vaccination status during the current season, fear of COVID-19 transmission,

133 and willingness to get the COVID-19 vaccine. The demographic and health  
134 characteristics were gender, age, education, marital status, annual household income (1  
135 USD was equal to 106.78 JPY, using 2020 conversion rates),<sup>23</sup> underlying disease, and  
136 smoking status. In line with a previous study,<sup>18</sup> we developed the following item to  
137 assess willingness to get the COVID-19 vaccine: “If a COVID-19 vaccine becomes  
138 available, I will get it.” The possible answers to this question were *yes* and *no*. Fear of  
139 COVID-19 transmission was assessed by asking “Do you fear COVID-19  
140 transmission?”, with *yes* and *no* as the possible responses.

141

#### 142 ***Data analysis***

143 We calculated frequencies and proportions for all variables. Descriptive statistics were  
144 also calculated by gender to reveal more detailed background factors. Logistic  
145 regression analysis was performed to calculate adjusted odds ratios (aORs) and 95%  
146 confidence intervals (CIs) for all variables to evaluate associations with willingness to  
147 get the COVID-19 vaccine. Because we hypothesized that gender was an important  
148 determinant in the current study, the analysis was stratified by gender. We adjusted for  
149 age; no adjustments were made for the other covariates because the purpose of this  
150 study was to detect target populations for future intervention programs. All *P*-values  
151 were two-sided, and statistical significance was set at  $P < .05$ . We used Stata/SE 16.1  
152 (StataCorp, College Station, TX, USA) for all analyses.

153

#### 154 **Results**

155 Table 1 shows the characteristics of the study population. Data on a total of 27,036  
156 participants (13,814 men and 13,222 women) were analyzed. We found that 43.0% of

157 the participants reported that they had received the influenza vaccine during the current  
158 season. Regarding fear of COVID-19 transmission, 74.0% indicated that they felt fear.  
159 Overall, 37.5% of the participants expressed that they would like to get a COVID-19  
160 vaccine if it becomes available.

161

162 Table 2 displays the characteristics of the study population by willingness to get the  
163 COVID-19 vaccine and gender. A total of 5,780 men (41.8%) and 4,367 women  
164 (33.0%) were willing to get the COVID-19 vaccine. Relatively high percentages of  
165 participants were willing to get the COVID-19 vaccine among those aged 60–65 years  
166 (men: 48.0%; women: 41.1%), those who had an underlying disease (men: 47.8%;  
167 women: 37.0%), those who felt fear of COVID-19 transmission (men: 49.5%; women:  
168 37.0%), and those who had received the influenza vaccine during the current season  
169 (men: 59.2%; women: 43.7%). These percentages were higher in men than in women.

170

171 Table 3 presents the factors associated with willingness to get the COVID-19 vaccine by  
172 gender. Men aged 50–59 years (aOR: 1.38; 95% CI: 1.02–1.86) and those aged 60–65  
173 years (aOR: 1.76; 95% CI: 1.30–2.40) were more willing to get the COVID-19 vaccine  
174 than were men aged 20–29 years. Conversely, women aged 30–39 years (aOR: 0.86;  
175 95% CI: 0.76–0.97) and those aged 40–49 years (aOR: 0.80; 95% CI: 0.71–0.91) were  
176 less willing to get the vaccine than were women aged 20–29 years. Regarding education  
177 level, compared with having a junior high or high school education, having a university  
178 or graduate school education was a facilitating factor for willingness to get the COVID-  
179 19 vaccine for men (aOR: 1.13; 95% CI: 1.04–1.22) but a barrier for women (aOR:  
180 0.83; 95% CI: 0.75–0.91).

181

182 For both men and women, a significantly higher likelihood of willingness to get the  
183 COVID-19 vaccine was observed among those who were married (men—aOR: 1.37;  
184 95% CI: 1.26–1.49; women—aOR: 1.30; 95% CI: 1.20–1.40), those with a higher  
185 annual household income (men—aOR: 1.91; 95% CI: 1.61–2.26; women—aOR: 1.32;  
186 95% CI: 1.13–1.53), those with an underlying disease (men—aOR: 1.43; 95% CI: 1.34–  
187 1.54; women—aOR: 1.29; 95% CI: 1.19–1.39), those who currently smoked (men—  
188 aOR: 1.20; 95% CI: 1.11–1.30; women—aOR: 1.36; 95% CI: 1.24–1.51), those who  
189 had been vaccinated against influenza during the current season (men—aOR: 3.28; 95%  
190 CI: 3.05–3.52; women—aOR: 2.53; 95% CI: 2.35–2.73), and those with a fear of  
191 COVID-19 transmission (men—aOR: 3.09; 95% CI: 2.85–3.35; women—aOR: 2.54;  
192 95% CI: 2.29–2.81).

193

## 194 **Discussion**

195 This study provides evidence on gender differences in the determinants of willingness  
196 to get the COVID-19 vaccine. In the present study, the percentage of people who were  
197 willing to get the COVID-19 vaccine was lower among women than among men  
198 (33.0% vs. 41.8%). This trend was similar to the findings of previous studies in  
199 developed countries.<sup>14, 19, 24, 25</sup> Notably, we found a gender gap in the associations of age  
200 and education level with willingness to get the COVID-19 vaccine: men who were older  
201 or had a higher level of education were more willing to get the vaccine, whereas women  
202 aged 30–49 years and those with a higher level of education were less willing to get the  
203 vaccine. Other factors showed similar trends for men and women: for both men and  
204 women, a higher likelihood of being willing to get the COVID-19 vaccine was observed  
205 in married participants, those with a higher annual household income, those who had an  
206 underlying disease, those who currently smoked, those who had been vaccinated against



207 influenza during the current season, and those with a fear of COVID-19 transmission.  
208 These findings give important insight into identifying target groups for improving  
209 COVID-19 vaccination intentions, especially among women.

210

211 The most notable finding of the present study was a gender gap in the associations of  
212 age and education with willingness to get the COVID-19 vaccine. As mentioned above,  
213 men who were older or had a higher level of education were more willing to get the  
214 vaccine, whereas women aged 30–49 years and those with a higher level of education  
215 were less willing to get the vaccine. For men, this finding is consistent with previous  
216 studies; older age and higher level of education are known facilitators for health  
217 protection, which should correlate with COVID-19 vaccination intentions.<sup>24, 26, 27</sup>

218 Conversely, the current results for women vary from the findings presented in these  
219 studies. This difference may be explained by a higher level of concern about adverse  
220 effects of the vaccine among women aged 30–49 years and among those with a  
221 relatively high level of education in Japan during the current study period. We  
222 considered that recent reporting on adverse effects following receipt of the human  
223 papillomavirus vaccine in major Japanese newspapers may have had a negative impact  
224 on the vaccination intentions of these groups.<sup>28</sup> These findings may imply the need for  
225 intervention in this population regarding COVID-19 vaccination.

226

227 The current study found that influenza vaccination status and fear of COVID-19  
228 transmission were strongly associated with willingness to get the COVID-19 vaccine  
229 among both men and women. These results are in line with previous studies.<sup>16, 17, 29, 30</sup> In  
230 the case of the 2009 influenza pandemic, perceived risk of infection translated into  
231 preventive behaviors, including vaccination.<sup>31</sup> Similarly, the experience of receiving a

232 vaccine have been shown to increase an individual's confidence in the efficacy and  
233 safety of other vaccines.<sup>29, 30</sup> Nevertheless, working-age people have fewer  
234 opportunities to receive the influenza vaccine compared with older adults because of the  
235 former group's busy work schedules.<sup>32</sup> These findings suggest that providing education  
236 about COVID-19 and influenza vaccination in the workplace may be an effective  
237 strategy to increase COVID-19 vaccine uptake.

238

239 In the current study, a higher likelihood of being willing to get the COVID-19 vaccine  
240 was observed among those who were married, those with a higher annual household  
241 income, those with an underlying disease, and those who currently smoked. Vulnerable  
242 populations, such as people with low socioeconomic status, are often found to have  
243 relatively poor health and to need support regarding their willingness to be vaccinated.<sup>16</sup>

244 In addition, a previous study on influenza vaccination suggests that single people are  
245 less willing to be vaccinated compared with their married counterparts because single  
246 people are not at risk of transmission from coresident family members.<sup>11</sup> Our finding  
247 regarding the presence of underlying disease may be related to the fear of COVID-19  
248 transmission because underlying disease a known risk factor for clinical severity of  
249 COVID-19 infection.<sup>24</sup> Only our finding on tobacco use was inconsistent with previous  
250 studies, which have found that smokers often tend to refuse vaccines regardless of the  
251 risk of clinical worsening associated with smoking.<sup>10, 11, 33</sup> Further studies should focus  
252 on confirming the relationship between smoking and COVID-19 vaccination intention.

253

254 Overall, we found that 37.5% of the working-age population in Japan was willing to get  
255 the COVID-19 vaccine. This percentage is not high enough to achieve herd immunity  
256 through the vaccination program.<sup>5</sup> This acceptance rate is lower than that in other

257 countries, such as China (91.3%), France (58.9%), the US (56.9%), and Russia  
258 (54.9%).<sup>6</sup> Furthermore, the acceptance rate is lower than the rate reported in a previous  
259 study in Japan (65.7%) that was conducted in September 2020.<sup>19</sup> One possible reason  
260 for the low vaccination intention in the current study may be tied to the research  
261 period.<sup>15</sup> Our study was conducted in December 2020, right after the start of the  
262 COVID-19 vaccination program in the UK and the US, and the media coverage of  
263 adverse effects was exaggerated.<sup>34, 35</sup> Another reason is that people of working age have  
264 been found to be less willing to get the COVID-19 vaccine compared with older  
265 adults,<sup>19</sup> which would affect the present results. These findings have important  
266 implications for vaccination intentions, although vaccination acceptance may change  
267 after the vaccine is available for administration among the working-age population.

268

269 The main strengths of this study are the large sample size and the use of a sample from  
270 throughout Japan. A limitation of this study is that we recruited study participants from  
271 an Internet research company's list of panelists. A previous study on the anti-vaccine  
272 movement reported that anti-vaccine messages were more prevalent on the Internet than  
273 in other sources.<sup>36</sup> Therefore, the participants in the current study may have been  
274 particularly likely to access anti-vaccine websites, and this should be taken into account  
275 when interpreting the results of our study. Additionally, we conducted the current study  
276 before the administration of the COVID-19 vaccination program in Japan; therefore, we  
277 could not provide participants with detailed information, such as the vaccination  
278 schedule, which may have affected their willingness to get the vaccine.

279

280 In conclusion, the current study revealed a gender gap in the associations of age and  
281 education level with willingness to get the COVID-19 vaccine. In particular, women

282 aged 30–49 years and those with a higher level of education were less willing to get the  
283 vaccine. These findings may imply the need for intervention for this population  
284 regarding COVID-19 vaccination. Providing education about COVID-19 and influenza  
285 vaccination in the workplace may be an effective strategy to increase COVID-19  
286 vaccine uptake.

287

## 288 **Acknowledgments**

289 We thank the current members of the CORoNaWork Project (listed in alphabetical  
290 order): Professor Yoshihisa Fujino (present chairperson of the study group), Dr. Hajime  
291 Ando, Professor Hisashi Eguchi, Dr. Kazunori Ikegami, Dr. Tomohiro Ishimaru, Dr.  
292 Arisa Harada, Dr. Ayako Hino, Dr. Kyoko Kitagawa, Dr. Kosuke Mafune, Professor  
293 Shinya Matsuda, Dr. Ryutaro Matsugaki, Professor Koji Mori, Dr. Keiji Muramatsu,  
294 Dr. Masako Nagata, Dr. Tomohisa Nagata, Ms. Ning Liu, Professor Akira Ogami, Dr.  
295 Rie Tanaka, Dr. Seiishiro Tateishi, Dr. Kei Tokutsu and Professor Mayumi Tsuji. All  
296 members are affiliated with the University of Occupational and Environmental Health,  
297 Japan.

298

## 299 **Funding details**

300 This study was supported and partly funded by the University of Occupational and  
301 Environmental Health, Japan; General Incorporated Foundation (Anshin Zaidan); The  
302 Development of Educational Materials on Mental Health Measures for Managers at  
303 Small-sized Enterprises; Health, Labour and Welfare Sciences Research Grants:  
304 Comprehensive Research for Women’s Healthcare (H30-josei-ippan-002) and Research  
305 for the Establishment of an Occupational Health System in Times of Disaster (H30-

306 roudou-ippan-007); scholarship donations from Chugai Pharmaceutical Co., Ltd.; the  
307 Collabo-Health Study Group; and Hitachi Systems, Ltd.

308

### 309 **Disclosure statement**

310 The authors declare no conflict of interest.

311

### 312 **References**

- 313 1. Mahase E. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95%  
314 after second dose, paper shows. *Bmj* 2020; 371:m4826. doi:10.1136/bmj.m4826.
- 315 2. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at  
316 Pandemic Speed. *N Engl J Med* 2020; 382:1969-73. doi:10.1056/NEJMp2005630.
- 317 3. Prime Minister of Japan and His Cabinet. Novel Coronavirus Vaccines. Tokyo:  
318 2021 Feb 17 [accessed 2021 Apr 1].  
319 <https://japan.kantei.go.jp/ongoingtopics/vaccine.html#vaccine05>.
- 320 4. Furuse Y, Sando E, Tsuchiya N, Miyahara R, Yasuda I, Ko YK, Saito M,  
321 Morimoto K, Imamura T, Shobugawa Y, et al. Clusters of Coronavirus Disease in  
322 Communities, Japan, January-April 2020. *Emerg Infect Dis* 2020; 26:2176-9.  
323 doi:10.3201/eid2609.202272.
- 324 5. Bartsch SM, O'Shea KJ, Ferguson MC, Bottazzi ME, Wedlock PT, Strych U,  
325 McKinnell JA, Siegmund SS, Cox SN, Hotez PJ, et al. Vaccine Efficacy Needed for a  
326 COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole  
327 Intervention. *Am J Prev Med* 2020; 59:493-503. doi:10.1016/j.amepre.2020.06.011.
- 328 6. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic  
329 Review of Vaccine Acceptance Rates. *Vaccines (Basel)* 2021; 9.  
330 doi:10.3390/vaccines9020160.
- 331 7. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping  
332 global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-  
333 scale retrospective temporal modelling study. *Lancet* 2020; 396:898-908.  
334 doi:10.1016/s0140-6736(20)31558-0.
- 335 8. Kuwabara N, Ching MS. A review of factors affecting vaccine preventable  
336 disease in Japan. *Hawai'i journal of medicine & public health : a journal of Asia Pacific*  
337 *Medicine & Public Health* 2014; 73:376-81.
- 338 9. Hori A, Yoshii S, Isaka Y, Wada K. Factors associated with participation in an  
339 ongoing national catch-up campaign against rubella: a cross-sectional internet survey  
340 among 1680 adult men in Japan. *BMC Public Health* 2021; 21:292.  
341 doi:10.1186/s12889-021-10340-8.
- 342 10. Wada K, Smith DR. Mistrust surrounding vaccination recommendations by the  
343 Japanese government: results from a national survey of working-age individuals. *BMC*  
344 *Public Health* 2015; 15:426. doi:10.1186/s12889-015-1772-8.

- 345 11. Wada K, Smith DR. Influenza vaccination uptake among the working age  
346 population of Japan: results from a national cross-sectional survey. *PLoS One* 2013;  
347 8:e59272. doi:10.1371/journal.pone.0059272.
- 348 12. Bonanni P, Zanella B, Santomauro F, Lorini C, Bechini A, Boccalini S. Safety  
349 and perception: What are the greatest enemies of HPV vaccination programmes?  
350 *Vaccine* 2018; 36:5424-9. doi:10.1016/j.vaccine.2017.05.071.
- 351 13. Suzuki Y, Sukegawa A, Nishikawa A, Kubota K, Motoki Y, Asai-Sato M, Ueda  
352 Y, Sekine M, Enomoto T, Hirahara F, et al. Current knowledge of and attitudes toward  
353 human papillomavirus-related disease prevention among Japanese: A large-scale  
354 questionnaire study. *The journal of obstetrics and gynaecology research* 2019; 45:994-  
355 1005. doi:10.1111/jog.13929.
- 356 14. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19  
357 vaccine acceptance in the US. *EClinicalMedicine* 2020; 26:100495.  
358 doi:10.1016/j.eclinm.2020.100495.
- 359 15. Wang K, Wong EL, Ho KF, Cheung AW, Yau PS, Dong D, Wong SY, Yeoh  
360 EK. Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine  
361 Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong,  
362 China: Repeated Cross-Sectional Surveys. *Vaccines (Basel)* 2021; 9.  
363 doi:10.3390/vaccines9010062.
- 364 16. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among  
365 adults in the United States: How many people would get vaccinated? *Vaccine* 2020;  
366 38:6500-7. doi:10.1016/j.vaccine.2020.08.043.
- 367 17. Chen M, Li Y, Chen J, Wen Z, Feng F, Zou H, Fu C, Chen L, Shu Y, Sun C. An  
368 online survey of the attitude and willingness of Chinese adults to receive COVID-19  
369 vaccination. *Hum Vaccin Immunother* 2021:1-10.  
370 doi:10.1080/21645515.2020.1853449.
- 371 18. Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ. Willingness to  
372 vaccinate against COVID-19 in Australia. *The Lancet Infectious diseases* 2020.  
373 doi:10.1016/s1473-3099(20)30559-4.
- 374 19. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan.  
375 *Vaccines (Basel)* 2021; 9. doi:10.3390/vaccines9010048.
- 376 20. Fujino Y, Ishimaru T, Eguchi H, Tsuji M, Tateishi S, Ogami A, Mori K,  
377 Matsuda S. Protocol for a nationwide Internet-based health survey in workers during the  
378 COVID-19 pandemic in 2020. *JUOEH* 2021:in press.  
379 doi:10.1101/2021.02.02.21249309.
- 380 21. Looi MK. Covid-19: Japan declares second state of emergency as Asia struggles  
381 with virus surge. *Bmj* 2021; 372:n141. doi:10.1136/bmj.n141.
- 382 22. Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far.  
383 *Bmj* 2021; 372:n421. doi:10.1136/bmj.n421.
- 384 23. Organisation for Economic Co-operation and Development. Exchange rates.  
385 Palis: 2021 [accessed 2021 Apr 1]. [https://data.oecd.org/conversion/exchange-  
386 rates.htm?fbclid=IwAR2Bn6JlF8WfAbVhwDEiKfHG0\\_rsTu-  
387 iLq1PW47o1ujebwc7CWF0e0wUx\\_A](https://data.oecd.org/conversion/exchange-rates.htm?fbclid=IwAR2Bn6JlF8WfAbVhwDEiKfHG0_rsTu-iLq1PW47o1ujebwc7CWF0e0wUx_A).
- 388 24. Alley SJ, Stanton R, Browne M, To QG, Khalesi S, Williams SL, Thwaite TL,  
389 Fenning AS, Vandelanotte C. As the Pandemic Progresses, How Does Willingness to  
390 Vaccinate against COVID-19 Evolve? *Int J Environ Res Public Health* 2021; 18.  
391 doi:10.3390/ijerph18020797.
- 392 25. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J,  
393 Schreyögg J, Stargardt T. Once we have it, will we use it? A European survey on

- 394 willingness to be vaccinated against COVID-19. *Eur J Health Econ* 2020; 21:977-82.  
395 doi:10.1007/s10198-020-01208-6.
- 396 26. Unroe KT, Evans R, Weaver L, Rusyniak D, Blackburn J. Willingness of Long-  
397 Term Care Staff to Receive a COVID-19 Vaccine: A Single State Survey. *J Am Geriatr*  
398 *Soc* 2020. doi:10.1111/jgs.17022.
- 399 27. Graffigna G, Palamenghi L, Boccia S, Barello S. Relationship between Citizens'  
400 Health Engagement and Intention to Take the COVID-19 Vaccine in Italy: A Mediation  
401 Analysis. *Vaccines (Basel)* 2020; 8. doi:10.3390/vaccines8040576.
- 402 28. Tsuda K, Yamamoto K, Leppold C, Tanimoto T, Kusumi E, Komatsu T, Kami  
403 M. Trends of Media Coverage on Human Papillomavirus Vaccination in Japanese  
404 Newspapers. *Clin Infect Dis* 2016; 63:1634-8. doi:10.1093/cid/ciw647.
- 405 29. Sakamoto A, Chanyasanha C, Sujirarat D, Matsumoto N, Nakazato M. Factors  
406 associated with pneumococcal vaccination in elderly people: a cross-sectional study  
407 among elderly club members in Miyakonojo City, Japan. *BMC Public Health* 2018;  
408 18:1172. doi:10.1186/s12889-018-6080-7.
- 409 30. Yi S, Nonaka D, Nomoto M, Kobayashi J, Mizoue T. Predictors of the uptake of  
410 A (H1N1) influenza vaccine: findings from a population-based longitudinal study in  
411 Tokyo. *PLoS One* 2011; 6:e18893. doi:10.1371/journal.pone.0018893.
- 412 31. Nguyen T, Henningsen KH, Brehaut JC, Hoe E, Wilson K. Acceptance of a  
413 pandemic influenza vaccine: a systematic review of surveys of the general public.  
414 *Infection and drug resistance* 2011; 4:197-207. doi:10.2147/idr.s23174.
- 415 32. Iwasa T, Wada K. Reasons for and against receiving influenza vaccination in a  
416 working age population in Japan: a national cross-sectional study. *BMC Public Health*  
417 2013; 13:647. doi:10.1186/1471-2458-13-647.
- 418 33. Matsui D, Shigeta M, Ozasa K, Kuriyama N, Watanabe I, Watanabe Y. Factors  
419 associated with influenza vaccination status of residents of a rural community in Japan.  
420 *BMC Public Health* 2011; 11:149. doi:10.1186/1471-2458-11-149.
- 421 34. Klimek L, Novak N, Hamelmann E, Werfel T, Wagenmann M, Taube C, Bauer  
422 A, Merk H, Rabe U, Jung K, et al. Severe allergic reactions after COVID-19  
423 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position  
424 statement of the German Allergy Societies: Medical Association of German  
425 Allergologists (AeDA), German Society for Allergology and Clinical Immunology  
426 (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).  
427 *Allergo journal international* 2021; 30:51-5. doi:10.1007/s40629-020-00160-4.
- 428 35. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the  
429 impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA.  
430 *Nature human behaviour* 2021; 5:337-48. doi:10.1038/s41562-021-01056-1.
- 431 36. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web.  
432 *Archives of disease in childhood* 2002; 87:22-5. doi:10.1136/adc.87.1.22.

433

434

435 Table 1. Characteristics of the study population.

	<i>n</i> (%)
Gender	
Men	13,814 (51.1)
Women	13,222 (48.9)
Age (years)	
20–29	1,905 (7.0)
30–39	4,858 (18.0)
40–49	8,011 (29.6)
50–59	9,012 (33.3)
60–65	3,250 (12.0)
Education level	
Junior high or high school	7,321 (27.1)
Vocational school or college	6,544 (24.2)
University or graduate school	13,171 (48.7)
Marital status	
Single	9,164 (33.9)
Divorced or widowed	2,843 (10.5)
Married	15,029 (55.6)
Annual household income (JPY)	
< 2,000,000	1,709 (6.3)
2,000,000–3,999,999	5,548 (20.5)
4,000,000–7,999,999	11,927 (44.1)
≥ 8,000,000	7,852 (29.1)
Underlying disease	
No	17,526 (64.8)
Yes	9,510 (35.2)
Smoking status	
Never smoked	14,587 (54.0)
Former smoker	5,445 (20.1)
Current smoker	7,004 (25.9)
Received the influenza vaccine during the current season	
No	15,411 (57.0)
Yes	11,625 (43.0)
Fear of COVID-19 transmission	
No	7,019 (26.0)
Yes	20,017 (74.0)
Willing to get the COVID-19 vaccine	
No	16,889 (62.5)
Yes	10,147 (37.5)

436 JPY: Japanese yen; COVID-19: coronavirus disease 2019

437



438 Table 2. Characteristics of the study population by willingness to get the COVID-19  
439 vaccine and gender.

	Men		Women	
	Willing	Unwilling	Willing	Unwilling
	<i>n</i> = 5,780 (41.8%) <i>n</i> (%)	<i>n</i> = 8,034 (58.2%) <i>n</i> (%)	<i>n</i> = 4,367 (33.0%) <i>n</i> (%)	<i>n</i> = 8,855 (67.0%) <i>n</i> (%)
<b>Age (years)</b>				
20–29	66 (34.4)	126 (65.6)	604 (35.3)	1,109 (64.7)
30–39	424 (37.8)	698 (62.2)	1,192 (31.9)	2,544 (68.1)
40–49	1,487 (39.1)	2,316 (60.9)	1,282 (30.5)	2,926 (69.5)
50–59	2,540 (41.9)	3,527 (58.1)	1,034 (35.1)	1,911 (64.9)
60–65	1,263 (48.0)	1,367 (52.0)	255 (41.1)	365 (58.9)
<b>Education level</b>				
Junior high or high school	1,562 (40.1)	2,335 (59.9)	1,212 (35.4)	2,212 (64.6)
Vocational school or college	818 (40.7)	1,194 (59.3)	1,523 (33.6)	3,009 (66.4)
University or graduate school	3,400 (43.0)	4,505 (57.0)	1,632 (31.0)	3,634 (69.0)
<b>Marital status</b>				
Single	1,195 (35.3)	2,189 (64.7)	1,724 (29.8)	4,056 (70.2)
Divorced or widowed	391 (39.9)	590 (60.1)	663 (35.6)	1,199 (64.4)
Married	4,194 (44.4)	5,255 (55.6)	1,980 (35.5)	3,600 (64.5)
<b>Annual household income (JPY)</b>				
< 2,000,000	219 (31.1)	486 (68.9)	289 (28.8)	715 (71.2)
2,000,000–3,999,999	897 (38.8)	1,414 (61.2)	1,056 (32.6)	2,181 (67.4)
4,000,000–7,999,999	2,585 (41.2)	3,694 (58.8)	1,866 (33.0)	3,782 (67.0)
≥ 8,000,000	2,079 (46.0)	2,440 (54.0)	1,156 (34.7)	2,177 (65.3)
<b>Underlying disease</b>				
No	3,201 (38.0)	5,221 (62.0)	2,844 (31.2)	6,260 (68.8)
Yes	2,579 (47.8)	2,813 (52.2)	1,523 (37.0)	2,595 (63.0)
<b>Smoking status</b>				
Never smoked	1,999 (38.4)	3,213 (61.6)	2,976 (31.7)	6,399 (68.3)
Former smoker	1,664 (44.4)	2,083 (55.6)	554 (32.6)	1,144 (67.4)
Current smoker	2,117 (43.6)	2,738 (56.4)	837 (38.9)	1,312 (61.1)
<b>Received the influenza vaccine during the current season</b>				
No	2,570 (30.6)	5,825 (69.4)	1,656 (23.6)	5,360 (76.4)
Yes	3,210 (59.2)	2,209 (40.8)	2,711 (43.7)	3,495 (56.3)
<b>Fear of COVID-19 transmission</b>				
No	986 (23.9)	3,146 (76.1)	542 (18.8)	2,345 (81.2)
Yes	4,794 (49.5)	4,888 (50.5)	3,825 (37.0)	6,510 (63.0)

440 COVID-19: coronavirus disease 2019; JPY: Japanese yen

441

442 Table 3. Factors associated with willingness to get the COVID-19 vaccine by gender.

	Men			Women		
	aOR <sup>a</sup>	(95% CI)	P-value	aOR <sup>a</sup>	(95% CI)	P-value
Age (years)						
20–29	1.00	-	-	1.00	-	-
30–39	1.16	(0.84–1.60)	.366	0.86	(0.76–0.97)	.015
40–49	1.23	(0.90–1.66)	.191	0.80	(0.71–0.91)	< .001
50–59	1.38	(1.02–1.86)	.039	0.99	(0.88–1.13)	.918
60–65	1.76	(1.30–2.40)	< .001	1.28	(1.06–1.55)	.010
Education level						
Junior high or high school	1.00	-	-	1.00	-	-
Vocational school or college	1.04	(0.93–1.16)	.461	0.93	(0.84–1.02)	.099
University or graduate school	1.13	(1.04–1.22)	.003	0.83	(0.75–0.91)	< .001
Marital status						
Single	1.00	-	-	1.00	-	-
Divorced or widowed	1.13	(0.97–1.31)	< .001	1.30	(1.16–1.46)	< .001
Married	1.37	(1.26–1.49)	< .001	1.30	(1.20–1.40)	< .001
Annual household income (JPY)						
< 2,000,000	1.00	-	-	1.00	-	-
2,000,000–3,999,999	1.45	(1.21–1.73)	< .001	1.20	(1.03–1.41)	.020
4,000,000–7,999,999	1.61	(1.36–1.90)	< .001	1.23	(1.06–1.42)	.007
≥ 8,000,000	1.91	(1.61–2.26)	< .001	1.32	(1.13–1.53)	< .001
Underlying disease						
No	1.00	-	-	1.00	-	-
Yes	1.43	(1.34–1.54)	< .001	1.29	(1.19–1.39)	< .001
Smoking status						
Never smoked	1.00	-	-	1.00	-	-
Former smoker	1.21	(1.11–1.33)	< .001	1.04	(0.93–1.16)	.521
Current smoker	1.20	(1.11–1.30)	< .001	1.36	(1.24–1.51)	< .001
Received the influenza vaccine during the current season						
No	1.00	-	-	1.00	-	-
Yes	3.28	(3.05–3.52)	< .001	2.53	(2.35–2.73)	< .001
Fear of COVID-19 transmission						
No	1.00	-	-	1.00	-	-
Yes	3.09	(2.85–3.35)	< .001	2.54	(2.29–2.81)	< .001

443 COVID-19: coronavirus disease 2019; aOR: adjusted odds ratio; CI: confidence

444 interval; JPY: Japanese yen

445 <sup>a</sup>Adjusted for age

446